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that does not violate the terms of the stimulus
plan, but could dramatically impact the care
of Medicaid recipients. Many doctors already
refuse to treat Medicaid patients because the
payments are so low that physicians end up

Jessica Ritsick, 2L

operating at a loss.
The Kaiser Family Foundation's Commission
on Medicaid and the Uninsured recently
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released a report stating that enrollment in

income decreases. The economy declines

Medicaid has increased due to the current

and

recession. Many insured individuals receive

cushion.

heath care benefits through their employers.

disproportionately

With the unemployment rate increasing,

unemployed.

however, employer-based health insurance
coverage is on the decline. Left with the
option of no insurance at all or paying out-

state

budgets

have

less

Unfortunately,

financial
recession
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poor

and

The Genetic Fountain of Youth
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of-pocket for private insurance, many of the

For centuries, explorers have searched for a

recently unemployed have found themselves

source of eternal youth. While many of these

with a third option: Medicaid. Those who

rituals and explorations would be considered

are eligible for the program are flocking to

bizarre

receive coverage.

recently found an internal pathway that, with

The Federal government shares Medicaid
funding with state governments. Many state

and mythical

today,

researchers

genetic manipulation, may lead to longevity
in mice - and potentially humans.

budgets have been unable to cover the surge

For decades, scientists have known that

of new enrollees in the program and fear their

reducing

upcoming budgets will not be able to shoulder

organisms leads to a significantly longer

these costs. The states found some relief in last

lifespan. Recently, however, researchers at

spring's stimulus plan, but many still worry

the University College London successfully

that there is not enough money appropriated

delayed the onset of many age-related diseases

in their budgets to adequately cover patients

and increased longevity in mice by genetically

without sending their own state finances into

blocking the S6 Kinase protein, a protein that

the red. Additionally, the stimulus funds came

is activated in response to food consumption.

with strings attached: states using the funds

The mice were found to have delayed markers

cannot restrict eligibility or complicate the

of aging and lived tventy percent longer than

coverage application process.

the non-genetically modified mice.

Many states are facing the challenge of

Other researchers haxve demonstrated that

finding or re-appropriating funds in their

similar longevity benefits in mice could be

budgets. Other states are considering cutting

achieved by manipulating the S6 Kinase

benefits or provider payments -an

pr otein through the use of a drug knowxn

option

caloric

intake

in experimental

to block the protein's action. The drug,

triggered when they ingest gluten-containing

Metformin, is one of the most commonly

products - found predominantly in wheat,

prescribed drugs

United States.

rye, and barley. There is no cure for Celiac

Metfonnin is used to treat Type 11Diabetes

Disease, but experts say that the disease can

and Polycystic Ovarian Syndrome. One of the

be effectively managed through strict dietary

drug's effects is to alter signaling pathways

measures. Thus. individuals who suffer from

in cells, 'tricking' the cells into thinking they

Celiac Disease - who commonly cannot

have fewer nutrients. Researchers hope to find

tolerate even trace amounts of gluten - rely

that drugs like Metfonnin will produce similar

heavily on labels to inform them as to whether

results to the manipulation of the S6 Kinase

a product is safe to consume.

in the

protein by deceiving cells into a starvation
response, analogous to what is observed
in long-lived calorie

restricted animals.

Eventually, researchers would like to test the
drug's effects on the lifespan of humans.

Although

knowledge

of Celiac

Disease

has been prevalent in the United States for
more than fifty years, it is not considered an
allergy and was not covered under the Food
Allergen Labeling and Consumer Protection

As the research of the phenomenon in humans

Act o/ 2004 (FAL CPA). While FALCPA did

continues, perhaps one day we will have our

not establish regulations for gluten-related

very own Fountain of Youth available at your

labeling, it did mandate that the FDA define

local pharmacy.

the term 'gluten-free' within four years of the
law's enactment date. The FDA continues to

The "Gluten-Free" Strugge

struggle with a comprehensive definition and
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has now missed that deadline by more than a

In January 2007, the United States Food
and Drug Administration "FDA) proposed a
regulation to define the term 'gluten-free' for
voluntary labeling. Nearly three years later,
the regulation remains in draft form and as
a result, there is no clear legal standard for
disclosing levels of gluten in food products.
The

lack of government regulation

for

labeling products as gluten-free continues to
cause serious problems for the United States
population who suffer from Celiac Disease.

year. The struggle lies in where to draw the
line for gluten-free. The FDA would like to
place the gluten ceiling at 20 parts per million
(ppm), stating that this is the level current
technology can reliably identify. However,
the proposed regulation has been met with
criticism from many groups who believe
this standard is not strong enough and is
potentially unsafe. Two independent gluten
free certification organizations, the GlutenFree Certification Organization and the Celiac
Sprue Association each say that they reliably

Celiac Disease is a chronic disorder xvhere an

certify products that are under 10 ppm. As the

immune system reaction to gluten proteins

FDA struggles with its definition, millions of

causes inflammation of the small intestine.

Americans continue to rely upon uniregulated

Individuals who are genetically predisposed

product labels.

to Celiac Disease sufter from symptoms

